Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISDN added to standard therapy for acute urinary retention due to BPH
IRCT20170417033489N5Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isosorbide dinitrate in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Increasing the effectiveness of drug therapy in the treatment of acute urinary retention. Started May 2019; status: completed.
02
Drugs
isosorbide dinitrate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20170417033489N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170417033489N5.